Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche receives FDA...

    Roche receives FDA clearance for its Procalcitonin assay to help clinicians effectively assess sepsis risk and manage sepsis patients

    Written by savita thakur thakur Published On 2016-06-27T09:25:22+05:30  |  Updated On 27 Jun 2016 9:25 AM IST
    Roche receives FDA clearance for its Procalcitonin assay to help clinicians effectively assess sepsis risk and manage sepsis patients

    Roche has recently announced that it has received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing solution for people with severe sepsis or septic shock. With this clearance, Roche is the first IVD company in the U.S to provide a fully integrated solution for sepsis risk assessment and management.


    PCT is a sepsis-specific biomarker associated with bacterial infection and PCT levels in blood can aid clinicians in assessing the risk of sepsis as well as managing the disease when present. The Elecsys BRAHMS PCT assay can aid in assessing the risk of critically ill patients to progress from severe sepsis to septic shock; and help determine the 28 day mortality risk in sepsis patients.


    "Given the prevalence of sepsis in the U.S. more than 1.6 million annual hospitalizations this clearance is an important advancement in its assessment and management," said Dr. Alan Wright, chief medical officer, Roche Diagnostics North America. "With such compelling clinical utilities and the automation advantages associated with Roche lab instrumentation, the Elecsys BRAHMS PCT test can provide healthcare professionals the confidence they need to manage this deadly disease."


    The clearance of Roche's PCT solution is a result of the U.S. multicenter Procalcitonin Monitoring Sepsis Study (MOSES). The novel trial design of Thermo Fisher Scientific's MOSES study leveraged the same patient samples to enable a "universal analysis" approach to demonstrate substantial equivalence to the FDA resulting in the clearance of the Elecsys BRAHMS PCT assay.

    Dr Alan WrightElecsys BRAHMS PCTMOSESPCTProcalcitoninProcalcitonin assayRochesepsissepsis patientssepsis riskUS Food & Drug AdministrationUSFDA
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok